Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation | OncLive

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma | OncLive

ICYMI: The FDA approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection. Full article - www.onclive.com/link/2698 | OncLive | Facebook

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs | OncLive

Targeted Therapy for Melanoma, Cancer Treatments Explained - MRA

Dr. Patel on the Sequencing of Immunotherapy and Targeted Therapy in BRAF-Mutant Melanoma | OncLive

Dr. Schuchter on Testing for a BRAF Mutation in Melanoma | OncLive

BRAF Mutation and Cancer

Case I: Newly Diagnosed BRAF Wild Type Advanced Melanoma | OncLive